{"id":"continuous-pivotal-l-ab","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting beta-lactamase, βL-AB increases the effectiveness of beta-lactam antibiotics, such as penicillins and cephalosporins, against bacteria that would otherwise be resistant to these antibiotics. This is particularly useful in treating infections caused by bacteria that produce beta-lactamase enzymes.","oneSentence":"βL-AB is a beta-lactamase inhibitor that works by inhibiting the bacterial enzyme beta-lactamase, which breaks down beta-lactam antibiotics.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:32:13.652Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of infections caused by bacteria that produce beta-lactamase enzymes, such as E. coli and Klebsiella pneumoniae"}]},"trialDetails":[{"nctId":"NCT05681442","phase":"PHASE4","title":"Beta-lactam Intermittent Versus Continuous Infusion and Combination Antibiotic Therapy in Sepsis","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-11-13","conditions":"Sepsis","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CID group"],"phase":"marketed","status":"active","brandName":"continuous pivotal βL-AB","genericName":"continuous pivotal βL-AB","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Continuous pivotal βL-AB is a treatment being studied for sepsis, as part of a clinical trial comparing it to intermittent pivotal βL-AB and combination antibiotic therapy. It is a small molecule modality, according to ChEMBL.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}